Artificial Intelligence
Rising demand for SiC chips: Bosch plans to acquire U.S. chipmaker TSI Semiconductors
<!– Name:DistributionId Value:8826051 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1214972 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:dbb7a563-7cd1-41ed-8516-4d46142c1967 –>
Stuttgart, Germany, April 26, 2023 (GLOBE NEWSWIRE) —
- Bosch chairman Dr. Stefan Hartung: “With this planned investment in the U.S., we are also increasing our semiconductor manufacturing, globally.”
- Third pillar for semiconductor business: following Reutlingen and Dresden in Germany, Bosch will in the future also make chips in Roseville, California.
- More chips: with the planned acquisition, Bosch will significantly expand its global portfolio of SiC semiconductors by the end of 2030.
- Electric cars as the driving force: SiC chips enable greater range and more efficient recharging.
Stuttgart, Germany – Bosch is expanding its semiconductor business with silicon carbide chips. The technology company plans to acquire assets of the U.S. chipmaker TSI Semiconductors, based in Roseville, California. With a workforce of 250, the company is a foundry for application-specific integrated circuits, or ASICs. Currently, it mainly develops and produces large volumes of chips on 200-millimeter silicon wafers for applications in the mobility, telecommunications, energy, and life sciences industries. Over the next years, Bosch intends to invest more than 1.5 billion USD in the Roseville site and convert the TSI Semiconductors manufacturing facilities to state-of-the-art processes. Starting in 2026, the first chips will be produced on 200-millimeter wafers based on the innovative material silicon carbide (SiC).
In this way, Bosch is systematically reinforcing its semiconductor business, and will have significantly extended its global portfolio of SiC chips by the end of 2030. Above all, the global boom and ramp-up of electromobility are resulting in huge demand for such special semiconductors. The full scope of the planned investment will be heavily dependent on federal funding opportunities available via the CHIPS and Science Act as well as economic development opportunities within the State of California. Bosch and TSI Semiconductors have reached an agreement to not to disclose any financial details of the transaction, which is subject to regulatory approval.
“With the acquisition of TSI Semiconductors, we are establishing manufacturing capacity for SiC chips in an important sales market while also increasing our semiconductor manufacturing, globally. The existing clean-room facilities and expert personnel in Roseville will allow us to manufacture SiC chips for electromobility on an even larger scale,” says Dr. Stefan Hartung, the chairman of the Bosch board of management. “The location in Roseville has existed since 1984. Over nearly 40 years, the U.S. company has built up vast expertise in semiconductor production. We will now be integrating this expertise into the Bosch semiconductor manufacturing network,” says Dr. Markus Heyn, member of the Bosch board of management and chairman of the Mobility Solutions business sector. “We are pleased to join a globally operating technology company with extensive semiconductor expertise. We are confident that our Roseville location will be a significant addition to Bosch’s SiC chipmaking operations,” says Oded Tal, CEO at TSI Semiconductors.
Acquisition of TSI Semiconductors creates new manufacturing capacity
The new location in Roseville will reinforce Bosch’s international semiconductor manufacturing network. Starting in 2026, following a retooling phase, first SiC chips will be produced on 200-millimeter wafers in a facility offering roughly 10,000 square meters of clean-room space. At an early stage, Bosch invested in the development and production of SiC chips. Since 2021, it has been using its own proprietary, highly complex processes to mass-produce them at its Reutlingen location near Stuttgart. In the future, Reutlingen will also produce them on 200-millimeters wafers. By the end of 2025, the company will have extended its clean-room space in Reutlingen from roughly 35,000 to more than 44,000 square meters. “SiC chips are a key component for electrified mobility. By extending our semiconductor operations internationally, we are strengthening our local presence in an important electric vehicle market,” Heyn says.
Demand for chips for the automotive industry remains high. By 2025, Bosch expects to have an average of 25 of its chips integrated in every new vehicle. The market for SiC chips is also continuing to grow fast – by 30 percent a year on average. The main drivers of this growth are the global boom and ramp-up of electromobility. In electric vehicles, SiC chips enable greater range and more efficient recharging, as they use up to 50 percent less energy. Installed in these vehicles’ power electronics, they ensure that a vehicle can drive a significantly longer distance on one battery charge – on average, the possible range is 6 percent greater than with silicon-based chips.
Systematic investments in pivotal semiconductor technology
Semiconductors are key to the success of all Bosch business areas. The company recognized the potential of this technology early on, and has been producing semiconductors for more than 60 years. Bosch is one of the few companies to have not only electronic and software expertise but also a profound understanding of microelectronics. It can combine this decisive competitive advantage with its strength in semiconductor manufacturing. The supplier of technology and services has been manufacturing semiconductors in Reutlingen since 1970. They are used both in the automotive sphere and in consumer electronics. Modern electronics in vehicles is also the basis for reducing traffic emissions, preventing road accidents, and efficient powertrains. Production at the Bosch wafer fab in Dresden (300-millimeter wafers) started in July 2021. At nearly one billion euros, the wafer fab is the biggest single investment in the company’s history.
In its wafer fabs in Reutlingen and Dresden, Bosch has invested more than 2.5 billion euros in total since 200-millimeter technology was introduced in 2010. On top of this, billions of euros have been invested in developing microelectronics. Independently of the investment now planned in the United States, the company announced in summer last year that it will be investing a further 3 billion euros in its semiconductor business in Europe, both as part of its investment planning and with the aid of the EU’s “Important Project of Common European Interest on Microelectronics and Communication Technologies” program.
Press photos:
https://www.bosch-mediaspace.de/mediaspace/usbstick/download/04242023_STILL_03.jpg?id=365258
https://www.bosch-mediaspace.de/mediaspace/usbstick/download/04242023_STILL_04.jpg?id=365259
https://www.bosch-mediaspace.de/mediaspace/usbstick/download/04242023_STILL_06.jpg?id=365260
About Bosch
Having established a presence in North America in 1906, today the Bosch Group employs nearly 37,000 associates in more than 100 locations in the region (as of Dec. 31, 2022). According to preliminary 2022 figures, Bosch generated consolidated sales of $15 billion in the U.S., Canada, and Mexico. For more information visit www.bosch.us, www.bosch.ca and www.bosch.mx.
The Bosch Group is a leading global supplier of technology and services. It employs roughly 420,000 associates worldwide (as of Dec. 31, 2022). The company generated sales of $93.1 billion in 2022. Its operations are divided into four business sectors: Mobility Solutions, Industrial Technology, Consumer Goods, and Energy and Building Technology. As a leading IoT provider, Bosch offers innovative solutions for smart homes, Industry 4.0, and connected mobility. Bosch is pursuing a vision of mobility that is sustainable, safe, and exciting. It uses its expertise in sensor technology, software, and services, as well as its own IoT cloud, to offer its customers connected, cross-domain solutions from a single source. The Bosch Group’s strategic objective is to facilitate connected living with products and solutions that either contain artificial intelligence (AI) or have been developed or manufactured with its help. Bosch improves quality of life worldwide with products and services that are innovative and spark enthusiasm. In short, Bosch creates technology that is “Invented for life.” The Bosch Group comprises Robert Bosch GmbH and its roughly 440 subsidiary and regional companies in some 60 countries. Including sales and service partners, Bosch’s global manufacturing, engineering, and sales network covers nearly every country in the world. With its more than 400 locations worldwide, the Bosch Group has been carbon neutral since the first quarter of 2020. The basis for the company’s future growth is its innovative strength. At 128 locations across the globe, Bosch employs roughly 84,800 associates in research and development, of which more than 44,000 are software engineers. In North America, Bosch employs approximately 3,500 associates in research and development.
Additional information is available online at www.bosch.com, www.iot.bosch.com, www.bosch-press.com, www.twitter.com/BoschPresse.
Exchange rate: 1 EUR = 1.0538
Attachment
Artificial Intelligence
Clinical Trial Analytics Services Market Projected to Reach $11.95 billion by 2030 – Exclusive Report by 360iResearch
PUNE, India, April 30, 2024 /PRNewswire/ — The report titled “Clinical Trial Analytics Services Market by Services (Clinical Data Analytics, Clinical Trial Data Management, Clinical Trial Planning & Monitoring), Component (Data Management & Integrity Services, Data Visualization & Dashboarding, Patient Recruitment & Retention Analytics), Stages, End-User, Deployment – Global Forecast 2024-2030” is now available on 360iResearch.com’s offering, presents an analysis indicating that the market projected to grow from a size of $5.42 billion in 2023 to reach $11.95 billion by 2030, at a CAGR of 11.93% over the forecast period.
“Global Expansion and Technological Advancements in Analytics Services”
Clinical trial analytics services are revolutionizing the landscape of medical research and drug development across the globe by utilizing cutting-edge data analytics and statistical methodologies to offer invaluable insights from clinical trial data. These services enhance trial efficiency, streamline costs, and boost accuracy, enabling stakeholders to refine study protocols, improve patient recruitment measures, ensure participant safety, and conduct in-depth effectiveness studies. Such analytics are pivotal in supporting clinical development strategies, facilitating smoother regulatory approvals, and aiding in ongoing market surveillance and informed decision-making. Challenges such as data privacy concerns and the substantial investments required, the sector continues to grow, driven by an increasing focus on advancing drug discoveries and the sheer volume of clinical trials. The Americas lead the market with robust clinical trial activity, supported by Europe’s push for more transparent and unified trial regulations. Meanwhile, the Middle East is emerging as a key player with significant healthcare investments, and the Asia Pacific region is recognized for its cost advantages and substantial patient demographics, becoming an attractive locale for clinical research organizations (CROs) and pharmaceutical advancements. This global momentum towards personalized medicine and heightened technology integration signifies a promising future for clinical trial analytics services in enhancing the efficacy and outcomes of clinical trials worldwide.
Download Sample Report @ https://www.360iresearch.com/library/intelligence/clinical-trial-analytics-services
“Revolutionizing Clinical Trials through Analytics: A New Era in Drug Discovery”
The pharmaceutical market is witnessing a significant transformation, marked by an increased focus on developing treatments for a broader spectrum of diseases, including those once deemed untreatable. This shift has propelled the expansion of clinical trials, which are now more complex due to advanced technologies, the inclusion of varied patient demographics, and stringent regulatory standards. As a result, managing and analyzing the vast amounts of data from these clinical trials has become a daunting task. Enter clinical trial analytics services, a game-changing solution that streamlines the management of these trials. These services offer indispensable insights for making strategic decisions, facilitating patient recruitment, ensuring regulatory compliance, and evaluating market potential, ultimately speeding up the delivery of new therapies. With the pharmaceutical sector’s deep investment in the quest for innovative treatments, the pivotal role of clinical trial analytics services in enhancing efficiency and driving success in drug development is clearer than ever.
“Revolutionizing Drug Development: The Power of Clinical Data Analytics”
Clinical data analytics plays a pivotal role in transforming drug development by meticulously analyzing information gathered during clinical trials. This process is key to unlocking valuable insights that lead to better clinical decisions, enhanced trial efficiency, and faster path to market for new treatments. It effectively decodes patterns, forecasts results, and elevates patient care by watching over potential adverse impacts closely. The compilation of a wide variety of data, ranging from patient demographics, clinical outcomes, to biomarkers, underpins these analytics. Innovative technologies including machine learning and artificial intelligence are at the forefront of dissecting these complex data sets to offer understandable insights. The cornerstone of this endeavor is maintaining supreme data quality, ensuring the conclusions drawn are solid and dependable. Clinical trial data management plays an instrumental role, orchestrating the collection, integration, and validation of data throughout its lifecycle. This meticulous process involves designing data capturing systems, setting standards for data collection, and closely monitoring to uphold the integrity of data. Additionally, the blueprinting and vigilant monitoring of clinical trials are critical, demanding clear goals, precise sample sizes, and thorough oversight to guarantee trial integrity and participant safety. Engaging patients in the trial process further underscores the focus on patient-centered approaches, ensuring trials are not just about data but also about the individuals who make the research possible.
Request Analyst Support @ https://www.360iresearch.com/library/intelligence/clinical-trial-analytics-services
“IQVIA Inc. at the Forefront of Clinical Trial Analytics Services Market with a Strong 10.57% Market Share”
The key players in the Clinical Trial Analytics Services Market include Laboratory Corporation of America Holdings, SGS S.A., QIAGEN N.V., ICON PLC, IQVIA Inc., and others. These prominent players focus on strategies such as expansions, acquisitions, joint ventures, and developing new products to strengthen their market positions.
“Introducing ThinkMi: Revolutionizing Market Intelligence with AI-Powered Insights for the Clinical Trial Analytics Services Market”
We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trial Analytics Services Market. ThinkMi stands out as your premier market intelligence partner, delivering unparalleled insights with the power of artificial intelligence. Whether deciphering market trends or offering actionable intelligence, ThinkMi is engineered to provide precise, relevant answers to your most critical business questions. This revolutionary tool is more than just an information source; it’s a strategic asset that empowers your decision-making with up-to-the-minute data, ensuring you stay ahead in the fiercely competitive Clinical Trial Analytics Services Market. Embrace the future of market analysis with ThinkMi, where informed decisions lead to remarkable growth.
Ask Question to ThinkMi @ https://app.360iresearch.com/library/intelligence/clinical-trial-analytics-services
“Dive into the Clinical Trial Analytics Services Market Landscape: Explore 184 Pages of Insights, 574 Tables, and 26 Figures”
PrefaceResearch MethodologyExecutive SummaryMarket OverviewMarket InsightsClinical Trial Analytics Services Market, by ServicesClinical Trial Analytics Services Market, by ComponentClinical Trial Analytics Services Market, by StagesClinical Trial Analytics Services Market, by End-UserClinical Trial Analytics Services Market, by DeploymentAmericas Clinical Trial Analytics Services MarketAsia-Pacific Clinical Trial Analytics Services MarketEurope, Middle East & Africa Clinical Trial Analytics Services MarketCompetitive LandscapeCompetitive PortfolioInquire Before Buying @ https://www.360iresearch.com/library/intelligence/clinical-trial-analytics-services
Related Reports:
Clinical Trial Support Services Market – Global Forecast 2024-2030In Silico Clinical Trials Market – Global Forecast 2024-2030Clinical Trial Supplies Market – Global Forecast 2024-2030About 360iResearch
Founded in 2017, 360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.
We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset — our people.
Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.
Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.
Contact 360iResearchMr. Ketan Rohom360iResearch Private Limited,Office No. 519, Nyati Empress,Opposite Phoenix Market City,Vimannagar, Pune, Maharashtra,India – 411014.Email: [email protected]: +1-530-264-8485India: +91-922-607-7550
To learn more, visit 360iresearch.com or follow us on LinkedIn, Twitter, and Facebook.
Logo: https://mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/clinical-trial-analytics-services-market-projected-to-reach-11-95-billion-by-2030—exclusive-report-by-360iresearch-302131960.html
Artificial Intelligence
Synthetik Applied Technologies LLC announces development of UrbanScale – a modeling platform for the prediction, characterization, and quantification of extreme urban heat
AUSTIN, Texas and LONDON, April 30, 2024 /PRNewswire/ — Synthetik Applied Technologies announces the development of UrbanScale, a tool to model and predict effects of extreme heat in urban areas, through a project funded by the National Oceanic and Atmospheric Association (NOAA). The physical characteristics of urban areas amplify heat effects resulting in what are known as urban heat islands — areas where surface temperatures are much higher than their surroundings. The UrbanScale tool addresses this climate peril with sophisticated analytic tools based on physics informed neural networks and cutting-edge machine learning to predict urban heat and help better understand and mitigate the risks associated with these extreme heat events. As a result of climate change, these events are expected to increase, impacting both the people that live in urban areas and the infrastructure on which they depend.
The UrbanScale platform shows significant promise to provide data on the severity of heat islands and their effects to better understand how they impact human health, energy use and damage to physical infrastructure. This information will provide a step-change in capability for government agencies, urban planners, and transportation authorities to direct efforts for mitigation and intervention. In particular, inclusion of demographic information into data pipelines will allow understanding of how urban heat effects may impact vulnerable or disadvantaged populations. Integration with climate forecasts and models will also provide unprecedented capabilities for forecasting risk associated with climate change.
Josh Hatfield, Director of Research and Development at Synthetik, said:
‘We are extremely grateful for the opportunity to study such an important issue. Extreme heat is already the largest cause of weather-related fatalities in the US, and climate change will only increase the importance of understanding heat in urban environments. Helping to meet that challenge fits directly into Synthetik’s mission.’
Synthetik COO Tim Brewer commented:
‘The UrbanScale tool will allow both our government and insurance partners to better characterize the risk of extreme heat in urban centers and promises to deliver critical insight on the way these events impact energy demands. We look forward to exploring its wide-ranging applications.’
Synthetik plans further development of UrbanScale with NOAA and other partners in the public and private sector.
For all inquiries: Contact Synthetik Applied Technologies PR [email protected]
Logo – https://mma.prnewswire.com/media/2067510/Synthetik_Applied_Technologies_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/synthetik-applied-technologies-llc-announces-development-of-urbanscale–a-modeling-platform-for-the-prediction-characterization-and-quantification-of-extreme-urban-heat-302132016.html
Artificial Intelligence
GLiNTECH – a Valiantys company, wins Atlassian Partner of the Year 2023 Services (APAC) award. Valiantys and GLiNTECH declared Finalists for Team Excellence and ITSM Solutions
PARIS, April 30, 2024 /PRNewswire/ — Atlassian announced today that GLiNTECH – a Valiantys company has won the Atlassian Partner of the Year 2023 Services (APAC) award. Valiantys and GLiNTECH were further declared finalists for the Team Excellence and ITSM Solutions awards, respectively.
This is an acknowledgement of their outstanding work for Atlassian customers during the calendar year 2023. This includes exceptional efforts in developing new business and driving innovative solutions for customer success.
“Our industry leading partners play a vital role in our customers’ continued success. We’re honored to highlight our top partners as award finalists this year, reflecting their ongoing commitment to delivering innovative solutions and unparalleled Atlassian services globally,” said Ko Mistry, Atlassian’s Head of Global Channels.
“We are delighted to be named as finalists for these awards from Atlassian, and we are particularly proud to celebrate GLiNTECH’s achievement in winning the Services (APAC) award.” said Emmanuel Benoit, Global Chief Executive Officer, Valiantys. “At Valiantys, embracing diversity of thought and challenging the ways our teams work has always provided Valiantys with a competitive edge to consistently deliver tangible results and value. We look to the future with unwavering determination and confidence as we continue to drive innovation and unlock potential for our customers around the globe.”
“We dedicate our IT Consulting Services and Custom Solutions to fulfilling our customers’ needs for success,” commented Dimitri Spyridopoulos, Chief Executive Officer GLiNTECH – a Valiantys company. “It’s an honor to be recognized by Atlassian as a finalist in two categories that reflect these efforts: Services and ITSM Solutions, and to be declared as winner for the Services award (APAC).”
For more information regarding this Press Release, contact: [email protected]
About Valiantys
Valiantys is a leading global consulting and services firm dedicated to Atlassian. The company accelerates business transformation by digitizing processes and modernizing teamwork, using the best agile methods and tools. Its Atlassian technical expertise is unparalleled and Valiantys supports its customers across the entire spectrum of projects on those platforms. As a recognized Agile at Scale, ITSM, and Cloud Specialized Partner, Valiantys help organizations accelerate time to value with Agile at scale, cloud, and ITSM implementations. Because teamwork requires more than just tools, the firm bridges the gap between applications and strategic practices such as SAFe® and ITIL. Over the last 15 years, Valiantys has helped more than 5,000 customers achieve their desired business outcomes at a reduced time to value, through improved team collaboration. More information about Valiantys can be found at https://www.valiantys.com/
About GLiNTECH – a Valiantys Company
GLiNTECH is a renowned Atlassian Platinum Partner headquartered in Australia and is the preferred choice for over 300 leading brands. The company has amassed more than 20 years of experience servicing enterprise clients across the Asia Pacific region, earning Atlassian Partner of the Year five times, including most recently for Professional Services. GLiNTECH is recognized as a Specialized Atlassian Cloud and ITSM partner. The company offers deep expertise in Licensing, Training, Support, Managed Services, Consulting, and Agile methodologies and has a proven record in providing reliable solutions while driving success within the Atlassian ecosystem. More information about GLiNTECH can be found here: https://www.glintech.com/
GLiNTECH was acquired by Valiantys in February 2024.
Photo – https://mma.prnewswire.com/media/2397508/GLiNTECH_2023_Services_award.jpg Logo – https://mma.prnewswire.com/media/1980997/Valiantys_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/glintech—a-valiantys-company-wins-atlassian-partner-of-the-year-2023-services-apac-award-valiantys-and-glintech-declared-finalists-for-team-excellence-and-itsm-solutions-302127386.html
-
Uncategorized6 days agoCherrypicks Partners with AWS DevAx Leading Cloud Technology Innovation for Hong Kong Enterprises
-
Artificial Intelligence5 days agoHikvision redefines urban mobility with AIoT-powered solutions at Intertraffic 2024
-
Artificial Intelligence5 days agoHITACHI ACQUIRES MA MICRO AUTOMATION OF GERMANY IN EFFORT TO ACCELERATE GLOBAL EXPANSION OF ROBOTIC SI BUSINESS IN THE MEDICAL AND OTHER FIELDS
-
Artificial Intelligence5 days ago
Greater efforts urged on sci-tech cooperation
-
Artificial Intelligence5 days agoWeb O.No: Metaverse and Web 3.0 stunted by internet chaos, warn 87% of business leaders
-
Uncategorized5 days ago
Xiao-I Corporation to Announce Full Year 2023 Results
-
Artificial Intelligence4 days agoCognitive Security Market Projected to Reach $134.26 billion by 2030 – Exclusive Report by 360iResearch
-
Artificial Intelligence5 days ago
IBM, Government of Canada, Government of Quebec Sign Agreements to Strengthen Canada’s Semiconductor Industry
